Strategic Partnerships Target potential collaboration with established pharma players seeking targeted protein degradation portfolios, leveraging DeuteRx’s DECS platform and recent M&A activity to position as a partner for late-stage or partnered NCE development.

NASH Portfolio Explore licensing or co-development opportunities around the Phase 2b NASH candidate PXL065 in collaboration with Poxel SA, highlighting potential for accelerated pathways and risk sharing with interested therapeutic area partners.

Intellectual Property Strength Emphasize DeuteRx’s robust patent footprint (>50 issued patents) and composition of matter protections to attract investors and in-licensing discussions, framing the value as defensible, differentiated chemical matter for new deals.

Deuterium Advantage Position DECS technology as a differentiator to entice pharma and biotech firms seeking novel mechanisms, with a focus on speed-to-market, de-risked development, and differentiated NCEs to shorten deal cycles.

Funding/Access Readiness Leverage current funding and modest revenue profile to pursue co-development or milestone-driven partnerships with mid-to-large pharmas looking for early-stage innovation, while highlighting recent Salarius Pharmaceuticals engagement as credibility signal.